Liu Wei, Zhang Xiangmei, Jiang Xiaokai, Dai Binyao, Zhang Liwen, Zhu Yang
Center for Medical Device Evaluation, National Medical Products Administration, Beijing, 100037, China.
Greater Bay Area Center for Medical Device Evaluation and Inspection, National Medical Products Administration, Shenzhen, 518045, China.
Bioact Mater. 2023 Nov 29;33:460-482. doi: 10.1016/j.bioactmat.2023.10.015. eCollection 2024 Mar.
Ischemic cardiomyopathy (ICM) affect millions of patients globally. Decellularized extracellular matrix materials (dECM) have components, microstructure and mechanical properties similar to healthy cardiac tissues, and can be manufactured into various forms of implantable biomaterials including injectable hydrogels or epicardial patches, which have been extensively reported to attenuate pathological left ventricular remodeling and maintain heart function. Recently, dECM medical devices for ICM treatment have been approved for clinical use or studied in clinical trials, exhibiting considerable translation potential. Cells, growth factors and other bioactive agents have been incorporated with different dECM materials to improve the therapeutic outcomes. In addition, more detailed aspects of the biological effects and mechanisms of dECM treatment are being revealed. This review summarized recent advances in dECM materials from variable sources for cardiac repair, including extraction of extracellular matrix, cell integration, smart manufacturing of injectable hydrogels and cardiac patch materials, and their therapeutic applications. Besides, this review provides an outlook on the cutting-edge development directions in the field.
缺血性心肌病(ICM)在全球范围内影响着数百万患者。去细胞化细胞外基质材料(dECM)具有与健康心脏组织相似的成分、微观结构和力学性能,可制成各种形式的可植入生物材料,包括可注射水凝胶或心外膜贴片,已有大量报道称这些材料可减轻病理性左心室重构并维持心脏功能。最近,用于ICM治疗的dECM医疗器械已获批准用于临床或正在临床试验中进行研究,显示出相当大的转化潜力。细胞、生长因子和其他生物活性剂已与不同的dECM材料结合,以改善治疗效果。此外,dECM治疗的生物学效应和机制的更详细方面也正在被揭示。本综述总结了来自不同来源的用于心脏修复的dECM材料的最新进展,包括细胞外基质的提取、细胞整合、可注射水凝胶和心脏贴片材料的智能制造及其治疗应用。此外,本综述还展望了该领域的前沿发展方向。